Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Testosterone cypionate
Drug ID BADD_D02171
Description Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.
Indications and Usage Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.[L1153]
Marketing Status approved
ATC Code Not Available
DrugBank ID DB13943
KEGG ID D00957
MeSH ID C016131
PubChem ID 441404
TTD Drug ID Not Available
NDC Product Code 60870-0252; 64025-0021; 0009-0086; 0143-9726; 52536-625; 62756-016; 0409-6562; 70700-288; 46439-8736; 62991-3132; 48087-0096; 0143-9659; 69097-536; 69097-802; 70700-289; 0574-0827; 76420-065; 51927-0189; 73774-016; 0591-4128; 38779-0164; 46204-0371; 60722-3016; 47781-911; 62756-015; 69097-537; 0143-9005; 63629-8706; 70700-290; 71225-127; 0009-0027; 47781-910; 63187-647; 63629-8705; 0517-1830; 51927-2706; 65089-0049; 73301-010; 0009-0347; 49803-006; 51552-0104; 63275-9982; 82393-114; 62756-017; 0409-6557; 0574-0820; 71205-289; 22552-0010; 43647-678; 0009-0085; 0009-0417; 50090-4147
UNII M0XW1UBI14
Synonyms testosterone 17 beta-cypionate | testosterone cypionate | testosterone 17 beta-cyclopentanepropionate | testosterone 17 beta-cyclopentylpropionate | Depo-Testosterone | Depo-Testosterone Cypionate | deposteron | Duratest | Testa-C | Testex Elmu | Andronate | Depostomead
Chemical Information
Molecular Formula C27H40O3
CAS Registry Number 58-20-8
SMILES CC12CCC3C(C1CCC2OC(=O)CCC4CCCC4)CCC5=CC(=O)CCC35C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hemiplegia17.01.04.0020.002621%Not Available
Hepatic neoplasm16.07.03.001; 09.04.03.001--Not Available
Hirsutism23.02.04.001; 05.05.01.005--
Hypersensitivity10.01.03.0030.011742%
Hypersomnia19.02.05.001; 17.15.01.0010.001048%
Hypertension24.08.02.0010.008597%
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.0110.001048%Not Available
Injection site bruising08.02.03.042; 24.07.06.017; 23.03.11.015; 12.07.03.0420.009436%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.012267%Not Available
Injection site induration12.07.03.007; 08.02.03.0070.004089%Not Available
Injection site inflammation12.07.03.009; 08.02.03.0080.002831%Not Available
Injection site irritation12.07.03.027; 08.02.03.0270.003565%Not Available
Injection site mass08.02.03.009; 12.07.03.0100.013000%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.065527%Not Available
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.0130.006395%Not Available
Injection site rash12.07.03.032; 08.02.03.032; 23.03.13.0100.003565%Not Available
Injection site reaction12.07.03.015; 08.02.03.0140.010694%
Injection site warmth12.07.03.036; 08.02.03.0360.004089%Not Available
Intracranial pressure increased17.07.02.0020.001573%Not Available
Jaundice cholestatic09.01.01.005--Not Available
Lacrimation increased06.08.02.0040.003565%
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.004089%
Libido decreased19.08.03.001; 21.03.02.0050.004089%
Libido increased21.03.02.007; 19.08.03.002--
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.004089%Not Available
Liver function test abnormal13.03.04.030--Not Available
Loss of libido19.08.03.0030.002097%Not Available
Lung disorder22.02.07.0010.002097%Not Available
Lymphadenopathy01.09.01.0020.003565%Not Available
Memory impairment19.20.01.003; 17.03.02.0030.004718%
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages